Status:
COMPLETED
Results of Mass Switch From Latanoprost to Travoprost
Lead Sponsor:
Singapore National Eye Centre
Conditions:
Glaucoma
Eligibility:
All Genders
Brief Summary
Prostaglandin analogs are a leading class of glaucoma drugs with a proven safety and efficacy for controlling IOP. They include latanoprost, bimatoprost, travoprost and unoprostone. Recently, the Sing...
Detailed Description
Aims: 1. To assess the feasibility of switching a large group of patients on treatment with latanoprost to travoprost. 2. To assess the efficacy and safety of travoprost compared to latanoprost after...
Eligibility Criteria
Inclusion
- Patients on treatment with latanoprost for at least 12 weeks; patients who are on additional beta-blockers topically will also be eligible.
- Written informed consent. -
Exclusion
- Patients on 3 or more topical medications.
- Recorded history of intolerance to travoprost.
- Recorded history of inefficacy of travoprost in controlling IOP.
- Patients on any additional topical medication other than beta-blockers.
- History of non-compliance.
- Involvement in any other concomitant study. -
Key Trial Info
Start Date :
April 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2008
Estimated Enrollment :
372 Patients enrolled
Trial Details
Trial ID
NCT00347126
Start Date
April 1 2006
End Date
April 1 2008
Last Update
May 12 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Singapore National Eye Centre
Singapore, Singapore, 168751